Proposed FDA guidelines to strengthen oversight on accelerated approval cancer drugs

After much talk about reforming its accelerated approval pathway, the Food and Drug Administration has taken a small step toward that goal. To “reduce clinical uncertainty,” the agency has proposed new guidelines for cancer drug developers that would tighten up requirements for clinical trials.